NCT05822453View on ClinicalTrials.gov

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2026

Conditions
Biliary Tract Carcinoma
Interventions
DRUG

Gemcitabine

Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle

DRUG

S1

S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle

DRUG

Tislelizumab

Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle

Trial Locations (1)

Unknown

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT05822453 - Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | Biotech Hunter | Biotech Hunter